tiprankstipranks
Trending News
More News >
ARS Pharmaceuticals (SPRY)
NASDAQ:SPRY
US Market

ARS Pharmaceuticals (SPRY) Income Statement

Compare
536 Followers

ARS Pharmaceuticals Income Statement

Last quarter (Q3 2025), ARS Pharmaceuticals's total revenue was $32.50M, a decrease of -62.46% from the same quarter last year. In Q3, ARS Pharmaceuticals's net income was $-51.15M. See ARS Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 89.15M$ 30.00K$ 1.32M$ 5.51M$ 17.84M
Gross Profit
$ 68.59M$ 30.00K$ 1.32M$ 5.29M$ 3.77M
Operating Expenses
$ 71.67M$ 67.55M$ 36.83M$ 24.75M$ 4.23M
Depreciation and Amortization
$ 79.00K$ 73.00K$ 319.00K$ 213.00K$ 6.00K
EBITDA
$ -3.00M$ -67.45M$ -35.20M$ -19.24M$ -463.00K
Operating Income
$ -3.08M$ -67.52M$ -35.52M$ -19.45M$ -469.00K
Other Income/Expenses
$ 11.37M$ 13.15M$ 834.00K$ -789.00K$ -596.00K
Pretax Income
$ 8.29M$ -54.37M$ -34.68M$ -20.24M$ -1.06M
Net Income
$ 8.00M$ -54.37M$ -34.68M$ -20.24M$ -1.06M
Per Share Metrics
Basic EPS
$ 0.08$ -0.57$ -0.87$ -0.70$ -0.03
Diluted EPS
$ 0.08$ -0.57$ -0.87$ -0.70$ -0.03
Weighted Average Shares Outstanding
96.94M 95.22M 39.96M 28.87M 34.70M
Weighted Average Shares Outstanding (Diluted)
102.39M 95.22M 39.96M 28.87M 34.70M
Currency in USD

ARS Pharmaceuticals Earnings and Revenue History